In a scopolamine-induced cognitive impairment mouse model of AD, the oral administration of AO for 30 days increased the levels of ACh and M1 receptors and decreased the activity of ACHE (Wang M. et al., 2018). The gene discussed is ACHE; the disease is Cognitive impairment.